Antitumor activity of PEGylated biodegradable nanoparticles for sustained release of docetaxel in triple-negative breast cancer

International Journal of Pharmaceutics

Volumn 473, Issue 1-2, 2014, Pages 55-63

  Palma, Giuseppe ^a,b   Conte, Claudia ^c   Barbieri, Antonio ^a   Bimonte, Sabrina ^a   Luciano, Antonio ^a   Rea, Domenica ^a   Ungaro, Francesca ^c   Tirino, Pasquale ^c   Quaglia, Fabiana ^c   Arra, Claudio ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b CNR   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Docetaxel; PEGylated nanoparticles; Powder for injection; Sustained release; Triple negative breast cancer

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; BETA ACTIN; CYCLODEXTRIN; DOCETAXEL; MACROGOL; NANOPARTICLE; POLYCAPROLACTONE; PROTEIN P53; 2-HYDROXYPROPYL-BETA-CYCLODEXTRIN; ANTINEOPLASTIC AGENT; BETA CYCLODEXTRIN DERIVATIVE; DELAYED RELEASE FORMULATION; ETHYLENE GLYCOL DERIVATIVE; PLASMA PROTEIN; POLY(EPSILON-CAPROLACTONE)-B-POLY(ETHYLENE GLYCOL); POLYESTER; POWDER; TAXOID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIODEGRADABILITY; CANCER INHIBITION; CANCER SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DISPERSION; DRUG EFFECT; DRUG EFFICACY; DRUG PENETRATION; FEMALE; HUMAN; HUMAN CELL; HYDRODYNAMICS; IN VITRO STUDY; IN VIVO STUDY; IONIC STRENGTH; MELTING POINT; MOUSE; NONHUMAN; PARTICLE SIZE; POWDER; PRIORITY JOURNAL; PROTEIN INTERACTION; SUSTAINED DRUG RELEASE; TRIPLE NEGATIVE BREAST CANCER; TUMOR VOLUME; TURBIDITY; ULTRASOUND; ZETA POTENTIAL; ADMINISTRATION AND DOSAGE; ANIMAL; CELL SURVIVAL; CHEMISTRY; DELAYED RELEASE FORMULATION; DRUG EFFECTS; MAMMARY NEOPLASMS, EXPERIMENTAL; NUDE MOUSE; PATHOLOGY; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; BETA-CYCLODEXTRINS; BLOOD PROTEINS; CELL LINE, TUMOR; CELL SURVIVAL; DELAYED-ACTION PREPARATIONS; ETHYLENE GLYCOLS; FEMALE; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE, NUDE; NANOPARTICLES; POLYESTERS; POWDERS; TAXOIDS; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR BURDEN;

EID: 84903831072     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2014.06.058     Document Type: Article

References (43)

1. J. Baker, J. Ajani, F. Scotte, D. Winther, M. Martin, M.S. Aapro, and M.G. von Docetaxel-related side effects and their management Eur. J. Oncol. Nurs. 13 2009 49 59
2. K.R. Bauer, M. Brown, R.D. Cress, C.A. Parise, and V. Caggiano Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer registry Cancer 109 2007 1721 1728 (Pubitemid 46668532)
3. H. Chen, S. Kim, W. He, H. Wang, P.S. Low, K. Park, and J.X. Cheng Fast release of lipophilic agents from circulating PEG-PDLLA micelles revealed by in vivo forster resonance energy transfer imaging Langmuir 24 2008 5213 5217
4. C. Conte, F. Ungaro, G. Maglio, P. Tirino, G. Siracusano, M.T. Sciortino, N. Leone, G. Palma, A. Barbieri, C. Arra, A. Mazzaglia, and F. Quaglia Biodegradable core-shell nanoassemblies for the delivery of docetaxel and Zn(II)-phthalocyanine inspired by combination therapy for cancer J. Control. Release 167 2013 40 52
5. C. Conte, I. d'Angelo, A. Miro, F. Ungaro, and F. Quaglia PEGylated polyester-based nanoncologicals Curr. Top. Med. Chem. 14 2014 1097 1114
6. I. d'Angelo, C. Conte, A. Miro, F. Quaglia, and F. Ungaro Core-shell nanocarriers for cancer. Part I: biologically-oriented design rules Expert Opin. Drug Deliv. 11 2014 283 297
7. F. Danhier, O. Feron, and V. Preat To exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anti-cancer drug delivery J. Control. Release 148 2010 135 146
8. E. Frei Albumin binding ligands and albumin conjugate uptake by cancer cells Diabetol. Metab. Syndr. 3 2011 11
9. P. Fumoleau Efficacy and safety of docetaxel in clinical trials Am. J. Health Syst. Pharm. 54 1997 S19 S24
10. W.J. Gradishar Albumin-bound paclitaxel: a next-generation taxane Expert Opin. Pharmacother. 7 2006 1041 1053 (Pubitemid 43949942)
11. S. Hirsjarvi, C. Passirani, and J.P. Benoit Passive and active tumour targeting with nanocarriers Curr. Drug Discov. Technol. 8 2011 188 196
12. S.J. Isakoff Triple-negative breast cancer: role of specific chemotherapy agents Cancer J. 16 2010 53 61
13. N.R. Jabir, S. Tabrez, G.M. Ashraf, S. Shakil, G.A. Damanhouri, and M.A. Kamal Nanotechnology-based approaches in anticancer research Int. J. Nanomed. 7 2012 4391 4408
14. M.R. Joshi, N. Yao, K.A. Myers, and Z. Li Human serum albumin and p53-activating peptide fusion protein is able to promote apoptosis and deliver fatty acid-modified molecules PLoS One 8 2013 e80926
15. D.W. Kim, S.Y. Kim, H.K. Kim, S.W. Kim, S.W. Shin, J.S. Kim, K. Park, M.Y. Lee, and D.S. Heo Multicenter phase II trial of Genexol-PM, a novel Cremophor-free, polymeric micelle formulation of paclitaxel, with cisplatin in patients with advanced non-small-cell lung cancer Ann. Oncol. 18 2007 2009 2014 (Pubitemid 350286241)
16. T.K. Kim, H.H. Yoo, E.J. Kim, B.Y. Lee, and J.H. Park Pharmacokinetic equivalence of Taxotere and SID530, a novel docetaxel formulation containing hydroxypropyl-beta-cyclodextrin in monkeys Arzneimittelforschung 62 2012 280 284
17. T. Lammers, F. Kiessling, W.E. Hennink, and G. Storm Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress J. Control. Release 161 2012 175 187
18. K.S. Lee, H.C. Chung, S.A. Im, Y.H. Park, C.S. Kim, S.B. Kim, S.Y. Rha, M.Y. Lee, and J. Ro Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer Breast Cancer Res. Treat. 108 2008 241 250 (Pubitemid 351311357)
19. S.W. Lee, M.H. Yun, S.W. Jeong, C.H. In, J.Y. Kim, M.H. Seo, C.M. Pai, and S.O. Kim Development of docetaxel-loaded intravenous formulation, Nanoxel-PM using polymer-based delivery system J. Control. Release 155 2011 262 271
20. K. Letchford, and H.M. Burt Copolymer micelles and nanospheres with different in vitro stability demonstrate similar paclitaxel pharmacokinetics Mol. Pharm. 9 2012 248 260
21. C. Liedtke, C. Mazouni, K.R. Hess, F. Andre, A. Tordai, J.A. Mejia, W.F. Symmans, A.M. Gonzalez-Angulo, B. Hennessy, M. Green, M. Cristofanilli, G.N. Hortobagyi, and L. Pusztai Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer J. Clin. Oncol. 26 2008 1275 1281
22. W.T. Lim, E.H. Tan, C.K. Toh, S.W. Hee, S.S. Leong, P.C. Ang, N.S. Wong, and B. Chowbay Phase I pharmacokinetic study of a weekly liposomal paclitaxel formulation (Genexol-PM) in patients with solid tumors Ann. Oncol. 21 2010 382 388
23. Q. Liu, R. Li, Z. Zhu, X. Qian, W. Guan, L. Yu, M. Yang, X. Jiang, and B. Liu Enhanced antitumor efficacy, biodistribution and penetration of docetaxel-loaded biodegradable nanoparticles Int. J. Pharm. 430 2012 350 358
24. H. Maeda, H. Nakamura, and J. Fang The EPR effect for macromolecular drug delivery to solid tumors: improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo Adv. Drug Deliv. Rev. 65 2013 71 79
25. A.S. Mikhail, and C. Allen Block copolymer micelles for delivery of cancer therapy: transport at the whole body, tissue and cellular levels J. Control. Release 138 2009 214 223
26. M.A. Moretton, D.A. Chiappetta, and A. Sosnik Cryoprotection- lyophilization and physical stabilization of rifampicin-loaded flower-like polymeric micelles J. R. Soc. Interface 9 2012 487 502
27. D.E. Owens III, and N.A. Peppas Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles Int. J. Pharm. 307 2006 93 102 (Pubitemid 41773257)
28. E. Pasquier, M. Kavallaris, and N. Andre Metronomic chemotherapy: new rationale for new directions Nat. Rev. Clin. Oncol. 7 2010 455 465
29. F. Quaglia, L. Ostacolo, R.G. De, M.I. La Rotonda, M. Ammendola, G. Nese, G. Maglio, R. Palumbo, and C. Vauthier Nanoscopic core-shell drug carriers made of amphiphilic triblock and star-diblock copolymers Int. J. Pharm. 324 2006 56 66 (Pubitemid 44548294)
30. F. Quaglia, L. Ostacolo, G. Nese, M. Canciello, R.G. De, F. Ungaro, R. Palumbo, M.I. La Rotonda, and G. Maglio Micelles based on amphiphilic PCL-PEO triblock and star-shaped diblock copolymers: potential in drug delivery applications J. Biomed. Mater. Res. A 87 2008 563 574
31. P. Rastogi, S.J. Anderson, H.D. Bear, C.E. Geyer, M.S. Kahlenberg, A. Robidoux, R.G. Margolese, J.L. Hoehn, V.G. Vogel, S.R. Dakhil, D. Tamkus, K.M. King, E.R. Pajon, M.J. Wright, J. Robert, S. Paik, E.P. Mamounas, and N. Wolmark Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27 J. Clin. Oncol. 26 2008 778 785 (Pubitemid 351264391)
32. S.R. Saptarshi, A. Duschl, and A.L. Lopata Interaction of nanoparticles with proteins: relation to bio-reactivity of the nanoparticle J. Nanobiotechnol. 11 2013 26
33. R. Savic, T. Azzam, A. Eisenberg, and D. Maysinger Assessment of the integrity of poly(caprolactone)-b-poly(ethylene oxide) micelles under biological conditions: a fluorogenic-based approach Langmuir 22 2006 3570 3578 (Pubitemid 43672524)
34. R. Savic, T. Azzam, A. Eisenberg, and D. Maysinger Assessment of the integrity of poly(caprolactone)-b-poly(ethylene oxide) micelles under biological conditions: a fluorogenic-based approach Langmuir 22 2006 3570 3578 (Pubitemid 43672524)
35. M. Shahin, and A. Lavasanifar Novel self-associating poly(ethylene oxide)-b-poly(epsilon-caprolactone) based drug conjugates and nano-containers for paclitaxel delivery Int. J. Pharm. 389 2010 213 222
36. T. Sorlie, R. Tibshirani, J. Parker, T. Hastie, J.S. Marron, A. Nobel, S. Deng, H. Johnsen, R. Pesich, S. Geisler, J. Demeter, C.M. Perou, P.E. Lonning, P.O. Brown, A.L. Borresen-Dale, and D. Botstein Repeated observation of breast tumor subtypes in independent gene expression data sets Proc. Natl. Acad. Sci. U. S. A. 100 2003 8418 8423 (Pubitemid 36842560)
37. V.J. Stella, and Q. He Cyclodextrins Toxicol. Pathol. 36 2008 30 42
38. F. Ungaro, C. Conte, L. Ostacolo, G. Maglio, A. Barbieri, C. Arra, G. Misso, A. Abbruzzese, M. Caraglia, and F. Quaglia Core-shell biodegradable nanoassemblies for the passive targeting of docetaxel: features, antiproliferative activity and in vivo toxicity Nanomedicine 8 2012 637 646
39. F. Ungaro, C. Conte, L. Ostacolo, G. Maglio, A. Barbieri, C. Arra, G. Misso, A. Abbruzzese, M. Caraglia, and F. Quaglia Core-shell biodegradable nanoassemblies for the passive targeting of docetaxel: features, antiproliferative activity and in vivo toxicity Nanomedicine 8 2012 637 646
40. J. Wu, S. Li, W. Jia, and F. Su Response and prognosis of taxanes and anthracyclines neoadjuvant chemotherapy in patients with triple-negative breast cancer J. Cancer Res. Clin. Oncol. 137 2011 1505 1510
41. H. Yagata, Y. Kajiura, and H. Yamauchi Current strategy for triple-negative breast cancer: appropriate combination of surgery, radiation, and chemotherapy Breast Cancer 18 2011 165 173
42. J. Yang, E. Lee, M. Ku, Y.M. Huh, and J.H. Cheong Functional nanoplatforms for enhancement of chemotherapeutic index Anticancer Agents Med. Chem. 13 2013 212 221
43. L. Zhang, Y. He, G. Ma, C. Song, and H. Sun Paclitaxel-loaded polymeric micelles based on poly(varepsilon-caprolactone)-poly(ethylene glycol)-poly(varepsilon-caprolactone) triblock copolymers: in vitro and in vivo evaluation Nanomedicine 8 2012 925 934